Cold Agglutinin Disease

Red blood cells clumped by cold antibodies
Red blood cells clumped by cold antibodies

Table of Contents

  1. What Cold Agglutinin Disease Is
  2. Pathophysiology: Complement-Mediated Hemolysis
  3. Primary and Secondary CAD
  4. Mycoplasma Pneumoniae and Secondary CAD
  5. Clinical Presentation
  6. Diagnosis: DAT, Cold Agglutinin Titers, and Lab Artifacts
  7. Treatment: Rituximab, Sutimlimab, and Complement Inhibitors
  8. Common Errors: Steroids, Cold Transfusions, Misdiagnosis Traps
  9. Long-Term Outcomes and Monitoring
  10. Key Research Papers
  11. Connections
  12. Featured Videos

What Cold Agglutinin Disease Is

Cold Agglutinin Disease (CAD) is a form of autoimmune hemolytic anemia (AIHA) in which pathological antibodies — called cold agglutinins — cause the destruction of red blood cells at temperatures below normal body temperature. These antibodies are immunoglobulin M (IgM) immunoglobulins that bind to red cell surface antigens, predominantly the I antigen (a carbohydrate antigen on the surface of adult red blood cells), when the blood cools in peripheral tissues such as the fingers, toes, ears, and nose — where temperatures can fall to 20–30°C during cold exposure. The immunoglobulin M antibodies then activate the complement cascade, coating the red cells with C3b fragments and driving their destruction primarily in the liver and spleen (extravascular hemolysis) by complement receptors on Kupffer cells and macrophages. In severe cases, the terminal complement complex (membrane attack complex, MAC) can form directly on the red cell surface, causing intravascular hemolysis and hemoglobinuria.

CAD accounts for approximately 15–25% of all cases of autoimmune hemolytic anemia. It is a rare disease — estimated incidence of approximately 1 per million per year in Northern Europe — but may be underdiagnosed because symptoms are often intermittent, cold-triggered, and attributed to Raynaud's phenomenon or other common conditions. It predominantly affects older adults, with a median age at diagnosis of approximately 65–72 years, and affects men and women nearly equally (unlike warm AIHA, which is more common in women). The disease can be chronic and debilitating, with anemia, cold-triggered acrocyanosis, and fatigue impairing daily activities — particularly in winter months or cold climates.

Back to Table of Contents

Pathophysiology: Complement-Mediated Hemolysis

The pathophysiology of CAD is fundamentally driven by the unique thermal properties of immunoglobulin M cold agglutinins and their interaction with the complement system. Understanding this mechanism explains both the clinical manifestations and the rationale for each treatment approach.

Immunoglobulin M Cold Agglutinins: Temperature-Dependent Binding

Normal adults carry low-titer cold agglutinins in their blood (titers typically ≤1:16 at 4°C) that are physiologically irrelevant. In CAD, a monoclonal or high-titer polyclonal immunoglobulin M antibody is present that binds red blood cell I antigen at the thermal amplitude (temperature range) that occurs in peripheral blood — typically 4°C to 30°C, sometimes as high as 37°C in highly pathogenic cold agglutinins. The I antigen is a branched polylactosamino glycan expressed on adult red cells; fetal red cells express the i antigen (unbranched precursor). Cold agglutinins in CAD most commonly target I antigen; those in infectious mononucleosis (Epstein-Barr virus, EBV) target i antigen; both types are immunoglobulin M.

When blood circulates through cold peripheral tissues and the temperature drops below the antibody's thermal amplitude, immunoglobulin M binds to the I antigen on the red cell surface. Immunoglobulin M is a pentameric molecule with high complement-activating capacity — a single immunoglobulin M molecule can activate the classical complement pathway. The antibody-antigen complex activates C1q, initiating the complement cascade: C1q → C4 → C2 → C3 convertase → cleavage of C3 into C3a (anaphylatoxin) and C3b (opsonin). C3b deposits on the red cell surface.

Complement-Mediated Destruction: The Two Pathways

When C3b-coated red cells return to the warm central circulation (37°C), the immunoglobulin M antibody dissociates from the red cell surface — but the C3b coating remains. This is critical: C3b persists on the cell surface even after the antibody detaches. C3b-coated red cells are recognized by complement receptor 1 (CR1) on hepatic Kupffer cells, which phagocytose and destroy the opsonized red cells — this is extravascular hemolysis in the liver. The spleen also participates via macrophage complement receptors. This is the primary hemolytic mechanism in most CAD patients.

When the complement cascade proceeds beyond C3b deposition — through C5 convertase to C5–C9 (the terminal complement complex, MAC) — intravascular hemolysis occurs: the MAC inserts into the red cell membrane, forming a pore that lyses the cell directly in the bloodstream. This releases hemoglobin into plasma (hemoglobinemia) and subsequently into urine (hemoglobinuria — dark or red-brown urine). Intravascular hemolysis is more severe and clinically dramatic and occurs predominantly during acute cold exposure or infectious exacerbations.

Why Complement Is the Therapeutic Target

The central role of complement in CAD — specifically the classical pathway (activated by immunoglobulin M) and C3 deposition driving extravascular hemolysis — explains why complement inhibitors are highly effective treatments. Blocking C1s (with sutimlimab) or C3 (with pegcetacoplan) interrupts hemolysis at its root cause, whereas anti-CD20 therapy (rituximab) depletes the B-cell clone producing the immunoglobulin M autoantibody. Corticosteroids, which work primarily by suppressing Fc receptor-mediated phagocytosis (the mechanism of warm AIHA), have minimal impact on complement-mediated hemolysis — explaining why steroids are largely ineffective in CAD.

Back to Table of Contents

Primary and Secondary CAD

The distinction between primary (chronic) CAD and secondary CAD fundamentally shapes prognosis and management approach.

Primary Cold Agglutinin Disease

Primary CAD is a chronic, clonal B-cell lymphoproliferative disorder. Despite the historical term "idiopathic," primary CAD is now recognized as almost always being driven by a small clonal B-cell population — most commonly resembling marginal zone lymphoma or lymphoplasmacytic lymphoma — that produces a monoclonal immunoglobulin M cold agglutinin (usually kappa light chain restriction). A 2014 study of bone marrow from 54 people with primary CAD found small, circumscribed clusters (nodules) of identical clonal B cells in 40 of them; the disease's cold agglutinins are made from the IGHV4-34 antibody gene. The MYD88 L265P mutation, typical of lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia, was not found in any of the 17 cases tested, and the authors concluded that this marrow disorder is a distinct B-cell lymphoma type that differs from lymphoplasmacytic lymphoma. Even when a frank lymphoma cannot be diagnosed by current criteria, the underlying clonal B-cell process persists indefinitely, explaining the chronic relapsing course and the rationale for B-cell-directed therapies.

Secondary CAD

Secondary CAD arises in the context of an identifiable underlying condition that drives — usually transiently — the production of cold agglutinins:

Back to Table of Contents

Mycoplasma Pneumoniae and Secondary CAD

Mycoplasma pneumoniae pneumonia — commonly known as "walking pneumonia" for its often mild clinical presentation — is the most important infectious trigger of secondary cold agglutinin disease and represents the classic teaching case of this association. Understanding this connection illustrates the molecular mimicry mechanism of infection-induced autoimmunity.

The Anti-I Antibody in Mycoplasma Infection

During Mycoplasma pneumoniae infection, the immune response generates immunoglobulin M antibodies against the organism's surface glycolipids. These bacterial surface antigens share structural similarities with the I blood group antigen on human red blood cells — specifically, both share a branched polylactosamino glycan core structure. Through molecular mimicry, the anti-Mycoplasma immunoglobulin M antibodies cross-react with the red cell I antigen, producing high-titer cold agglutinins (often reaching titers of 1:256 or higher during active infection). This explains why cold agglutinin testing was historically used as a clinical aid for diagnosing Mycoplasma pneumonia (cold agglutinins ≥1:64 in a patient with pneumonia strongly suggested Mycoplasma before specific serologic tests became available).

Clinical Features and Course

Mycoplasma-induced CAD typically appears 1–3 weeks after the onset of respiratory symptoms, coinciding with peak immunoglobulin M antibody titers. The hemolytic anemia can be clinically significant, particularly in older patients or those with cardiorespiratory reserve limitations. Unlike primary CAD, Mycoplasma-induced cold agglutinin disease is self-limited — as the infection resolves and the immunoglobulin M antibody titer falls over weeks, hemolysis abates. Treatment focuses on appropriate antibiotic therapy for the Mycoplasma infection (azithromycin or a fluoroquinolone), supportive care for anemia, and cold avoidance during the acute phase.

Epstein-Barr Virus and Anti-i Antibodies

Infectious mononucleosis from Epstein-Barr virus generates a different cold agglutinin specificity: the anti-i antibody (targeting the unbranched i antigen expressed on fetal red cells and retained at low levels on adult cells). Epstein-Barr virus-induced cold agglutinin disease is clinically similar to Mycoplasma-induced CAD — self-limited and resolving with the infection — but the anti-i specificity can serve as a useful clinical distinguishing point between the two infectious etiologies.

Back to Table of Contents

Clinical Presentation

The clinical manifestations of CAD arise from two processes: chronic complement-mediated hemolytic anemia, and cold-triggered microvascular agglutination in peripheral vessels during cold exposure.

Chronic Hemolytic Anemia

Most patients with primary CAD have a chronic, moderately severe hemolytic anemia with hemoglobin levels typically ranging from 7–10 g/dL. Symptoms of anemia — fatigue, weakness, exertional dyspnea, pallor, and reduced exercise tolerance — are the most common presenting complaints. The anemia is normocytic or mildly macrocytic (because the reticulocyte response releases young, large red cells). Laboratory signs of hemolysis are present: elevated lactate dehydrogenase (LDH), elevated indirect bilirubin, low or undetectable haptoglobin. Many patients have periods of clinical stability punctuated by acute hemolytic episodes triggered by cold exposure, infections, or surgical procedures under hypothermic conditions (e.g., open-heart surgery on cardiopulmonary bypass — CAD can cause catastrophic hemolysis if bypass circuit temperatures drop below the thermal amplitude).

Cold-Triggered Acrocyanosis

The pathognomonic physical finding of CAD is acrocyanosis — a blue-to-purple discoloration of the fingers, toes, ears, tip of the nose, and lips that develops on exposure to cold temperatures. When the patient's hands are placed in cool water (15–20°C) or exposed to cold air, the extremities turn blue-purple within minutes. The mechanism is red cell agglutination in the small vessels of the extremities when blood cools — the agglutinated cell clusters obstruct microvascular flow, causing ischemic discoloration. This blanches and resolves as the extremities rewarm. The phenomenon can closely mimic Raynaud's phenomenon, but differs in mechanism: Raynaud's involves vasospasm of arterioles, while CAD acrocyanosis involves intravascular red cell agglutination.

Hemoglobinuria and Seasonal Exacerbation

In severe acute episodes — particularly after sustained cold exposure — intravascular hemolysis can release enough hemoglobin to color the urine dark brown to port-wine red (hemoglobinuria). This is a dramatic finding that often brings patients to urgent medical attention. Primary CAD characteristically worsens in winter months and improves in summer — a seasonal pattern reflecting the temperature-dependence of complement activation. Patients living in cold climates may have significantly more disease activity than those in warmer regions.

Back to Table of Contents

Diagnosis: DAT, Cold Agglutinin Titers, and Lab Artifacts

The diagnosis of CAD requires both confirming the presence of cold agglutinin-mediated hemolysis and evaluating for underlying causes. Several important laboratory pitfalls can mislead clinicians unfamiliar with the disorder.

Direct Antiglobulin Test (DAT): Positive for C3d, NOT IgG

The direct antiglobulin test (Coombs test) is the cornerstone diagnostic test for autoimmune hemolytic anemia. In CAD, the DAT is positive for complement (C3d) and typically negative for immunoglobulin G (IgG). This is the critical distinguishing feature: in warm AIHA (the more common form), the DAT is positive for immunoglobulin G (and may also be positive for C3d). In CAD, the immunoglobulin M antibody dissociates from the red cell surface at 37°C body temperature, leaving only the C3d coating detectable. A DAT positive for C3d alone in a patient with hemolytic anemia points strongly to CAD. For an accurate DAT, blood is kept at 37°C from collection until the serum is separated to prevent the immunoglobulin M antibody from dissociating during processing and re-agglutinating cells in the tube before testing.

Cold Agglutinin Titer

Cold agglutinin titers are measured by serially diluting serum and testing each dilution for the ability to agglutinate red cells at 4°C. A titer of ≥1:64 at 4°C is considered clinically significant for CAD. Titers ≥1:256 are common in primary CAD; titers ≥1:512 indicate severe disease. The thermal amplitude — the highest temperature at which agglutination occurs — is more clinically significant than the absolute titer: an antibody with high thermal amplitude (agglutinates at 30°C or above) is more pathogenic than a high-titer antibody that only agglutinates at 4°C because more blood is exposed to temperatures at or below the amplitude during normal activity. Titers are measured on blood kept at 37°C until serum separation to prevent false-negative results from ex vivo agglutination depleting antibody.

Complete Blood Count Laboratory Artifacts from Cold Agglutinins

Cold agglutinins cause a well-recognized artifact on automated complete blood counts: cold-agglutinated red cells form doublets and clusters that the automated counter interprets as single, large cells, producing a spuriously elevated mean corpuscular volume (MCV) and a falsely low red blood cell count (RBC). This discordance — a very high MCV (sometimes >130 fL, far outside the normal range of 80–100 fL) with a very low RBC — in a patient with anemia strongly suggests CAD. If the blood sample is warmed to 37°C before rerunning through the counter, the agglutinates disperse and the MCV normalizes while the RBC count rises. Performing this "warm repeat complete blood count (CBC)" is both diagnostic and practical, ensuring accurate cell counts for clinical management.

Workup for Underlying Cause

The standard workup for newly diagnosed CAD includes:

Back to Table of Contents

Treatment: Rituximab, Sutimlimab, and Complement Inhibitors

Treatment of CAD is guided by disease severity, underlying cause, and subtype (primary vs. secondary). Mild primary CAD with well-compensated anemia may require only lifestyle modifications and cold avoidance. Symptomatic anemia, disabling acrocyanosis, or hemolysis impacting quality of life warrant pharmacologic therapy.

Cold Avoidance: The Essential Non-Pharmacologic Intervention

Cold avoidance is both the simplest and one of the most effective interventions in primary CAD. The cold-avoidance measures described for CAD are warm gloves and hats, staying out of air-conditioned rooms, warming food and drinks before eating, no whole-body cold immersion (swimming), and, in severe cases, moving to a warmer climate. Blood for transfusion is warmed to 37°C through a blood warmer before infusion — cold banked blood can trigger acute hemolytic episodes. Surgical procedures carry special risk: the anesthesiology team needs to know the diagnosis so that intraoperative patient warming is maintained, particularly in cardiac surgery where bypass circuit temperatures are deliberately lowered.

Rituximab-Based Regimens: First-Line B-Cell Depletion

Rituximab (anti-CD20 monoclonal antibody) depletes the clonal B-cell population producing the pathogenic immunoglobulin M cold agglutinin. In a prospective study of 37 rituximab courses in 27 patients, rituximab alone helped about half (overall response rate 54%, nearly all partial responses), with a median response duration of 11 months. Re-treatment worked in 6 of 10 patients who relapsed. In a prospective trial of 29 patients, rituximab plus fludarabine produced a response in 76% (complete response in 21%), with an estimated median response duration of more than 66 months, but severe (grade 3–4) blood-count drops in 41%. In a Nordic prospective trial of 45 patients, rituximab plus bendamustine produced a response in 71% (complete response in 40%, 18 of 45); the 10th percentile of response duration had not been reached after 32 months. Severe neutrophil drops occurred in 33% of these patients, but infections in 11%, and the authors concluded that the combination may be considered as first-line therapy for patients with CAD who need treatment. Each of these figures comes from a single trial without a comparison group, not from a head-to-head comparison. Treatment begins with evaluation for hepatitis B (rituximab can reactivate latent hepatitis B virus, HBV), and Pneumocystis prophylaxis is commonly part of these regimens.

Sutimlimab: The First U.S. Food and Drug Administration-Approved Therapy for Cold Agglutinin Disease

Sutimlimab is a humanized monoclonal antibody targeting C1s, the serine protease component of the C1 complex at the initiation of the classical complement pathway. By blocking C1s, sutimlimab prevents C1 from cleaving C4 and C2, halting the classical pathway at its very first step and preventing C3b deposition on red cells. The U.S. Food and Drug Administration (FDA) approved sutimlimab in February 2022 as the first therapy specifically approved for the disease; its label covers the treatment of hemolysis in adults with cold agglutinin disease. The CARDINAL trial (24 patients with a recent transfusion, open-label, no comparison group) found that 13 of 24 (54%) met its main goal; mean hemoglobin rose by 2.6 g/dL at weeks 23–26 and stayed above 11 g/dL from week 3 on, bilirubin returned to normal by week 3, 71% needed no transfusion from week 5 through week 26, and fatigue lessened from week 1. The drug is given as a weight-based intravenous infusion weekly for the first two weeks, then every two weeks. Key limitation: sutimlimab inhibits the classical pathway but not the alternative or lectin complement pathways, so it does not provide protection against encapsulated bacteria normally opsonized via these pathways — the FDA label calls for vaccination against encapsulated bacteria (pneumococcal, meningococcal, and Haemophilus influenzae type b) at least two weeks before treatment, as with other complement inhibitor therapies.

In the long-term part of the CADENZA study (Part B, 2024), patients without recent transfusions received sutimlimab for a median of 99 weeks. Mean hemoglobin stayed at or above 11.0 g/dL on treatment, compared with 9.3 g/dL at the start, and no meningococcal infections occurred. In the 9 weeks after the drug was stopped, hemolysis markers returned close to their starting levels, so the benefit lasts only while the drug is given.

Pegcetacoplan: C3 Inhibitor

Pegcetacoplan is a C3-targeted complement inhibitor that blocks the complement cascade at the C3 step — downstream of C1s but upstream of the terminal pathway. By inhibiting C3, pegcetacoplan blocks both extravascular hemolysis (C3b-mediated phagocytosis) and intravascular hemolysis (MAC formation). Clinical trial data in CAD are emerging, and pegcetacoplan is an established treatment for paroxysmal nocturnal hemoglobinuria (PNH), another complement-mediated hemolytic anemia.

Back to Table of Contents

Common Errors: Steroids, Cold Transfusions, Misdiagnosis Traps

Several management errors are particularly common in CAD and can cause serious harm. Awareness of these pitfalls is as important as knowledge of appropriate therapy.

Corticosteroids Work Poorly as Primary Therapy

This is perhaps the most important teaching point in CAD management: corticosteroids are largely ineffective in cold agglutinin disease and are not used as primary therapy. This is the opposite of warm AIHA, where prednisone is the standard first-line treatment. The distinction matters clinically: corticosteroids work primarily by blocking Fc receptor-mediated phagocytosis of immunoglobulin G-coated red cells by macrophages. In CAD, the primary hemolytic mechanism is complement (C3b)-mediated and Fc receptor-independent — Kupffer cells and macrophages recognize C3b via complement receptors, not Fc receptors, making corticosteroid-mediated Fc receptor blockade largely irrelevant. High-dose corticosteroids occasionally produce modest transient benefit through non-specific immunosuppression, but at doses causing significant toxicity, and the benefit rarely justifies the risk for chronic CAD. Clinicians confusing CAD with warm AIHA and prescribing prednisone expose patients to prolonged steroid toxicity without meaningful benefit.

Cold Blood Transfusions Can Trigger Hemolysis

Blood transfusions in CAD are given through an in-line blood warmer maintaining the blood at 37°C during infusion. Administering cold (4°C banked blood) to a patient with high-thermal-amplitude cold agglutinins can trigger acute, severe intravascular hemolysis. The clinical team giving blood (including emergency and operating room staff) needs to know the diagnosis before any transfusion.

Misdiagnosis as Raynaud's Phenomenon

The cold-triggered acrocyanosis of CAD can easily be misinterpreted as Raynaud's phenomenon or livedo reticularis, leading to years of diagnostic delay. Key distinguishing features: CAD acrocyanosis involves all exposed extremities simultaneously (not sequential color changes per the classic Raynaud triple-color response of white → blue → red); it does not respond to calcium channel blockers or sympatholytic drugs; and it is accompanied by the laboratory signs of hemolytic anemia that are absent in primary Raynaud's. Any patient with "Raynaud's" who has anemia, elevated lactate dehydrogenase, or low haptoglobin deserves cold agglutinin evaluation.

Back to Table of Contents

Long-Term Outcomes and Monitoring

Primary cold agglutinin disease is a chronic, relapsing condition that requires long-term management. With modern therapies, most patients can achieve adequate hemoglobin control and significant improvement in quality of life. The underlying clonal B-cell process persists indefinitely, and most patients who achieve remission with rituximab-based therapy eventually relapse and require re-treatment. Sutimlimab provides continuous hemolysis control with ongoing administration but does not eradicate the underlying clone.

Long-term monitoring for underlying lymphoma progression is essential — while most primary CAD clones remain indolent for decades, a proportion evolve into frank lymphoplasmacytic lymphoma, Waldenström's macroglobulinemia, or other B-cell lymphomas requiring systemic chemotherapy. Annual assessment including serum protein electrophoresis, immunoglobulin quantification, and clinical evaluation for lymphadenopathy or systemic symptoms is appropriate. Computed tomography imaging is done periodically or when clinical features suggest lymphoma progression. For patients on sutimlimab or other complement inhibitors, up-to-date pneumococcal and meningococcal vaccination matters, and a fever is treated as a reason for prompt medical evaluation, given the risk of encapsulated bacterial infections during classical pathway inhibition.

Quality of life in well-controlled CAD can be substantially normal. The most impactful non-pharmacologic intervention — relocating to a warmer climate or avoiding cold environments through lifestyle modification — is often underutilized but can dramatically reduce hemolytic burden and acrocyanosis without pharmacologic risk. Patient education about cold avoidance, blood warming requirements, and the need to inform surgical and anesthesia teams before any procedure is a cornerstone of chronic CAD management.

Back to Table of Contents

Key Research Papers

  1. Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91(4):460–466. — PubMed PMID: 16585012
  2. Röth A, Barcellini W, D'Sa S, et al. Sutimlimab in cold agglutinin disease. N Engl J Med. 2021;384(14):1323–1334. — PubMed PMID: 33826820
  3. Berentsen S, Randen U, Tjønnfjord GE. Cold agglutinin-mediated autoimmune hemolytic anemia. Hematol Oncol Clin North Am. 2015;29(3):455–471. — PubMed PMID: 26043385
  4. Berentsen S, Tjønnfjord GE. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev. 2012;26(3):107–115. — PubMed PMID: 22330255
  5. Berentsen S, Randen U, Vagan AM, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010;116(17):3180–3184. — PubMed PMID: 20634373
  6. Jäger U, D'Sa S, Schörgenhofer C, et al. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood. 2019;133(9):893–901. — PubMed PMID: 30559259
  7. Berentsen S, Barcellini W, D'Sa S, et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood. 2020;136(4):480–488. — PubMed PMID: 32374875
  8. Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122(7):1114–1121. — PubMed PMID: 23757733
  9. Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103(8):2925–2928. — PubMed PMID: 15070665
  10. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012;367(9):826–833. — PubMed PMID: 22931316
  11. Arthold C, Skrabs C, Mitterbauer-Hohendanner G, et al. Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings. Wien Klin Wochenschr. 2014;126(11–12):376–382. — PubMed PMID: 24842748
  12. Berentsen S. Diagnosis and management of cold agglutinin disease. Hematology Am Soc Hematol Educ Program. 2025;2025(1):295–304. — PubMed PMID: 41348049
  13. Randen U, Trøen G, Tierens A, et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica. 2014;99(3):497–504. — PubMed PMID: 24143001
  14. Berentsen S, Randen U, Oksman M, et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood. 2017;130(4):537–541. — PubMed PMID: 28533306
  15. Röth A, Berentsen S, Barcellini W, et al. Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B. EClinicalMedicine. 2024;74:102733. — PubMed PMID: 39091672

Search PubMed for more: Cold agglutinin disease Sutimlimab CAD Rituximab CAD

Back to Table of Contents

Connections

Back to Table of Contents